Australasian Gastrointestinal Pathology Society (AGPS) consensus guidelines for universal defective mismatch repair testing in colorectal carcinoma.
暂无分享,去创建一个
A. Gill | C. Rosty | M. Yozu | M. Kumarasinghe | I. Brown
[1] Ya-nan Zhang,et al. The Prognostic Value of Deficient Mismatch Repair in Stage II–IVa Nasopharyngeal Carcinoma in the Era of IMRT , 2020, Scientific Reports.
[2] P. Dunne,et al. Punctate MLH1 mismatch repair immunostaining in colorectal cancer , 2019, Histopathology.
[3] Aung Ko Win,et al. Cancer Risks for PMS2-Associated Lynch Syndrome. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] C. Gilks,et al. Artefactual punctate MLH1 staining can lead to erroneous reporting of isolated PMS2 loss , 2018, Histopathology.
[5] W. Frankel,et al. Two-stain immunohistochemical screening for Lynch syndrome in colorectal cancer may fail to detect mismatch repair deficiency , 2018, Modern Pathology.
[6] O. Basturk,et al. Immunohistochemical null-phenotype for mismatch repair proteins in colonic carcinoma associated with concurrent MLH1 hypermethylation and MSH2 somatic mutations , 2018, Familial Cancer.
[7] C. Rosty,et al. Yield of Universal Testing for DNA Mismatch Repair Protein Deficiency in Colorectal Carcinoma From an Australian Community-based Practice , 2018, bioRxiv.
[8] A. Gill,et al. Real world experience of BRAFV600E mutation specific immunohistochemistry in colorectal carcinoma. , 2018, Pathology.
[9] Ludmila V. Danilova,et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade , 2017, Science.
[10] P. Møller,et al. Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database , 2017, Gut.
[11] M. Ladanyi,et al. Universal screening for microsatellite instability in colorectal cancer in the clinical genomics era: new recommendations, methods, and considerations , 2017, Familial Cancer.
[12] M. Jenkins,et al. Costs and outcomes of Lynch syndrome screening in the Australian colorectal cancer population , 2018, Journal of gastroenterology and hepatology.
[13] W. Frankel,et al. Molecular genetics of microsatellite-unstable colorectal cancer for pathologists , 2017, Diagnostic Pathology.
[14] A. Mattia,et al. A tailored approach to BRAF and MLH1 methylation testing in a universal screening program for Lynch syndrome , 2017, Modern Pathology.
[15] Aung Ko Win,et al. Tumor testing to identify lynch syndrome in two Australian colorectal cancer cohorts , 2017, Journal of gastroenterology and hepatology.
[16] E. Steyerberg,et al. Cost-effectiveness of routine screening for Lynch syndrome in endometrial cancer patients up to 70years of age. , 2016, Gynecologic oncology.
[17] R. Pai,et al. A Practical Approach to the Evaluation of Gastrointestinal Tract Carcinomas for Lynch Syndrome , 2016, The American journal of surgical pathology.
[18] E. Kuipers,et al. Cost-effectiveness of routine screening for Lynch syndrome in colorectal cancer patients up to 70 years of age , 2016, Genetics in Medicine.
[19] P. Devilee,et al. Combined mismatch repair and POLE/POLD1 defects explain unresolved suspected Lynch syndrome cancers , 2015, European Journal of Human Genetics.
[20] P. Møller,et al. Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database , 2015, Gut.
[21] F. Gao,et al. Combined Microsatellite Instability, MLH1 Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group Study , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] B. Leggett,et al. Clinicopathological and molecular features of sessile serrated adenomas with dysplasia or carcinoma , 2015, Gut.
[23] A. Rashid,et al. Assessment of BRAF V600E Status in Colorectal Carcinoma: Tissue-Specific Discordances between Immunohistochemistry and Sequencing , 2015, Molecular Cancer Therapeutics.
[24] A. Barkun,et al. American Gastroenterological Association Technical Review on the Diagnosis and Management of Lynch Syndrome. , 2015, Gastroenterology.
[25] F. Gao,et al. Impact of an immunohistochemistry-based universal screening protocol for Lynch syndrome in endometrial cancer on genetic counseling and testing. , 2015, Gynecologic oncology.
[26] M. Kattan,et al. Comparative effectiveness of screening strategies for Lynch syndrome. , 2015, Journal of the National Cancer Institute.
[27] S. Gruber,et al. Hereditary colorectal cancer syndromes: American Society of Clinical Oncology Clinical Practice Guideline endorsement of the familial risk-colorectal cancer: European Society for Medical Oncology Clinical Practice Guidelines. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] H. Mackay,et al. Performance characteristics of screening strategies for Lynch syndrome in unselected women with newly diagnosed endometrial cancer who have undergone universal germline mutation testing , 2014, Cancer.
[29] W. Frankel,et al. Colon and endometrial cancers with mismatch repair deficiency can arise from somatic, rather than germline, mutations. , 2014, Gastroenterology.
[30] Y. Niv,et al. How reliable is immunohistochemical staining for DNA mismatch repair proteins performed after neoadjuvant chemoradiation? , 2014, Human pathology.
[31] Markku Miettinen,et al. Detection of the BRAF V600E Mutation in Colon Carcinoma: Critical Evaluation of the Imunohistochemical Approach , 2014, The American journal of surgical pathology.
[32] J. Church,et al. Guidelines on Genetic Evaluation and Management of Lynch Syndrome: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer , 2014, The American Journal of Gastroenterology.
[33] A. Bojesen,et al. Heterogenous mismatch-repair status in colorectal cancer , 2014, Diagnostic Pathology.
[34] V. Georgoulias,et al. Prognostic and predictive significance of MSI in stages II/III colon cancer. , 2014, World journal of gastroenterology.
[35] A. Chou,et al. BRAFV600E immunohistochemistry in conjunction with mismatch repair status predicts survival in patients with colorectal cancer , 2013, Modern Pathology.
[36] Aung Ko Win,et al. BRAFV600E Immunohistochemistry Facilitates Universal Screening of Colorectal Cancers for Lynch Syndrome , 2013, The American journal of surgical pathology.
[37] J. Hornick,et al. Immunohistochemistry using the BRAF V600E mutation‐specific monoclonal antibody VE1 is not a useful surrogate for genotyping in colorectal adenocarcinoma , 2013, Histopathology.
[38] R. Ward,et al. Population-based molecular screening for Lynch syndrome: implications for personalized medicine. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] P. Møller,et al. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts , 2013, Gut.
[40] J. Potter,et al. Identification of Lynch syndrome among patients with colorectal cancer. , 2012, JAMA.
[41] A. Spurdle,et al. Correlation of tumour BRAF mutations and MLH1 methylation with germline mismatch repair (MMR) gene mutation status: a literature review assessing utility of tumour features for MMR variant classification , 2012, Journal of Medical Genetics.
[42] Marc S. Williams,et al. Lynch syndrome screening implementation: business analysis by a healthcare system. , 2011, The American journal of managed care.
[43] C. Boland,et al. Strategies to Identify the Lynch Syndrome Among Patients With Colorectal Cancer , 2011, Annals of Internal Medicine.
[44] M. Kloor,et al. Biallelic MLH1 SNP cDNA expression or constitutional promoter methylation can hide genomic rearrangements causing Lynch syndrome , 2011, Journal of Medical Genetics.
[45] H. Zentgraf,et al. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody , 2011, Acta Neuropathologica.
[46] Michael S. Rentz,et al. Immunohistochemical Staining for DNA Mismatch Repair Proteins in Intestinal Tract Carcinoma: How Reliable are Biopsy Samples? , 2011, The American journal of surgical pathology.
[47] R. Yantiss,et al. Neoadjuvant Therapy Induces Loss of MSH6 Expression in Colorectal Carcinoma , 2010, The American journal of surgical pathology.
[48] A. Gill,et al. Immunohistochemistry for PMS2 and MSH6 alone can replace a four antibody panel for mismatch repair deficiency screening in colorectal adenocarcinoma , 2010, Pathology.
[49] A. Bateman,et al. DNA mismatch repair enzyme immunohistochemistry in colorectal cancer: a comparison of biopsy and resection material , 2010, Pathology.
[50] R. Labianca,et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] C. Boland,et al. Report from the Jerusalem workshop on Lynch syndrome-hereditary nonpolyposis colorectal cancer. , 2010, Gastroenterology.
[52] Heather Hampel,et al. The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer , 2010, Genetics in Medicine.
[53] Laura H. Tang,et al. Immunohistochemistry as First-line Screening for Detecting Colorectal Cancer Patients at Risk for Hereditary Nonpolyposis Colorectal Cancer Syndrome: A 2-antibody Panel May be as Predictive as a 4-antibody Panel , 2009, The American journal of surgical pathology.
[54] Jukka-Pekka Mecklin,et al. Ten years after mutation testing for Lynch syndrome: cancer incidence and outcome in mutation-positive and mutation-negative family members. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[55] Heather Hampel,et al. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[56] G. Parmigiani,et al. Whole pelvic helical tomotherapy for locally advanced cervical cancer: technical implementation of IMRT with helical tomothearapy , 2009, Radiation oncology.
[57] R. Houlston,et al. Systematic review of microsatellite instability and colorectal cancer prognosis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[58] J. Mecklin,et al. The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC) , 1991, Diseases of the colon and rectum.
[59] M. Ladanyi,et al. Secondary mutation in a coding mononucleotide tract in MSH6 causes loss of immunoexpression of MSH6 in colorectal carcinomas with MLH1/PMS2 deficiency , 2013, Modern Pathology.
[60] Ewout W Steyerberg,et al. The PREMM(1,2,6) model predicts risk of MLH1, MSH2, and MSH6 germline mutations based on cancer history. , 2011, Gastroenterology.
[61] Suet Yi Leung,et al. Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3′ exons of TACSTD1 , 2009, Nature Genetics.
[62] Randall W Burt,et al. ACG Clinical Guideline: Genetic Testing and Management of Hereditary Gastrointestinal Cancer Syndromes , 2015, The American Journal of Gastroenterology.
[63] Jeffrey R. Botkin,et al. Summary of Recommendations: The Evaluation of Genomic Applications , 2022 .